Table 2

Principal growth hormone therapy trials in short SGA patients

Definitions SGA/short	GH dose/protocol	n	At start			Delta height (Ht) SDS						Final Ht		Delta bone age	Ref
Definitions SGA/short	GH dose/protocol	n	Age	Ht SDS	HV SDS	1y	2y	3y	4y	5y	6y	n	Ht SDS	Delta bone age	Ref
<−2 SDS	Untreated	12	5.18	−2.91		0.07	−0.03								15
	0.033 mg/kg/d	16	4.4	−3.29		1.09	0.45	0.18						1
	0.067 mg/kg/d	20	4.63	−3.22		1.43	0.7	0.41						1
<−1.88 SDS	Untreated	29	7.8	−2.6								15	−2.3		12
	0.033 mg/kg/d	41	7.3	−3						2.2		28	−1.1	1.4	16
	0.067 mg/kg/d	38	7.2	−3.1						2.6		26	−0.9	1.3
<−2 SDS	Placebo 6 months then 0.02 mg/kg/d for 2.5y	18	8.24	−3.16	−1.63										17
	Placebo 6 months then 0.06 mg/kg/d for 2.5y	20	8.16	−3.36	−0.64
	0.02 mg/kg/d for 3y, 1y off	15	8.4	−3.1	0.1		0.66	0.77	−0.3					1.15	18
	0.06 mg/kg/d for 3y, 1y off	40	8.1	−3.2	−1		1.25	1.61	−0.22					1.27
	0.02 for 2y, 0.06 for 3rd y, 1y off	23	7.9	−3.1	−0.7		0.66	0.93	−0.25					1.13
<−2 SDS	Median 0.027 mg/kg/d	396	8.6	−2.9				0.9						1.47	19
	Median 0.033 mg/kg/d	593	9.2	−2.8								16	−2.4		20
<−2 SDS/<−2.5 SDS	Untreated	13	4.9	−3.4	−0.6		0.2								21
	0.067 mg/kg/d	20	5.4	−3.5	−0.9		2.1							1.35
	0.1 mg/kg/d	19	5.1	−3.7	−0.7		2.5							1.33
<−2 SDS/<−2.5 SDS	0.077 mg/kg/d for 2y, 2y off, then 0.066 mg/kg/d for 2y	5	4.4	−3.5	−1						−1.8				22
	0.077 mg/kg/d for 2y	13							<−2		∼−1.4
<−2 SDS/<−2.5 SDS	Untreated	47	12.8	−3.2								33	−2.7		23
	0.067 mg/kg/d	102	12.7	−3.2				−2.1				91	−2.1
<10th centile not GHD	Untreated	20	10.7	−1.97								20	−1.9		24
<10th centile HD	0.038 mg/kg/d	29*	10.9	−2.28								29	−1.8